Page last updated: 2024-11-12

amenamevir

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ASP2151: a herpesvirus helicase-primase inhibitor, in a guinea pig model of genital herpes; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11397521
CHEMBL ID4297592
SCHEMBL ID2238614
MeSH IDM0577737

Synonyms (36)

Synonym
n-(2,6-dimethylphenyl)-n-[2-[4-(1,2,4-oxadiazol-3-yl)anilino]-2-oxo-ethyl]-1,1-dioxo-thiane-4-carboxamide
n-(2,6-dimethylphenyl)-n-(2-{[4-(1,2,4-oxadiazol-3-yl)phenyl]amino}-2-oxoethyl)tetrahydro-2h-thiopyran-4-carboxamide 1,1-dioxide
asp2151
amenamevir
94x46kw4ae ,
amenamevir [inn]
asp 2151
unii-94x46kw4ae
841301-32-4
n-(2,6-dimethylphenyl)-n-(2-((4-(1,2,4-oxadiazol-3-yl)phenyl)amino)-2-oxoethyl)-1,1-dioxothiane-4-carboxamide
amenamevir [jan]
amenamevir [who-dd]
asp-2151
amenamevir [mi]
S5552
SCHEMBL2238614
amenalief (tn)
amenamevir (jan/inn)
D10564
HY-14809
CS-8093
n-(2-((4-(1,2,4-oxadiazol-3-yl)phenyl)amino)-2-oxoethyl)-n-(2,6-dimethylphenyl)tetrahydro-2h-thiopyran-4-carboxamide 1,1-dioxide
DB11701
AKOS032954202
EX-A1700
BS-17608
n-(2,6-dimethylphenyl)-n-[2-[4-(1,2,4-oxadiazol-3-yl)anilino]-2-oxoethyl]-1,1-dioxothiane-4-carboxamide
SB19732
BCP29135
CCG-269570
Q27271708
D84108
CHEMBL4297592
NCGC00538163-01
AC-35855
DTXSID101027753

Research Excerpts

Overview

Ammenvir is a helicase-primase inhibitor of herpes simplex virus (HSV) and varicella-zoster virus (VZV) It is used for the treatment of herpes zoster in Japan. Amenamevir is an inhibito.

ExcerptReferenceRelevance
"Amenamevir (AMNV) is a helicase-primase inhibitor with antiviral activity against herpesviruses [herpes simplex viruses (HSV)-1 and -2, and varicella-zoster virus], which are associated with the development of acute herpetic pain (AHP) and postherpetic neuralgia. "( Inhibitory effect of amenamevir on acute herpetic pain and postherpetic neuralgia in mice infected with herpes simplex virus-1.
Andoh, T; Kanayama, S; Kawabata, A; Matsumoto, T; Nozawa, N; Osaki, M; Tanbo, S; Ueda, Y; Uta, D, 2020
)
2.32
"Amenamevir is a helicase-primase inhibitor of herpes simplex virus (HSV) and varicella-zoster virus (VZV) and is used for the treatment of herpes zoster in Japan. "( Viral ribonucleotide reductase attenuates the anti-herpes activity of acyclovir in contrast to amenamevir.
Daikoku, T; Sato, N; Shiraki, K; Takemoto, M; Tan, L; Yoshida, Y, 2020
)
2.22
"Amenamevir is a potent helicase-primase inhibitor and a novel class of antiviral agent other than nucleoside compounds, such as aciclovir, valaciclovir and famciclovir. "( Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study.
Honda, M; Imafuku, S; Kato, T; Katsuramaki, T; Kawashima, M; Nakayama, J; Nemoto, O; Watanabe, D, 2017
)
3.34
"Amenamevir is a nonnucleoside antiherpes virus compound available for treating herpes zoster infections. "( Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults.
den Adel, M; Garcia-Hernandez, A; Groenendaal-van de Meent, D; Katashima, M; Kato, K; Kusawake, T; Ohtsu, Y; Takada, A, 2017
)
2.15
"Amenamevir (ASP2151) is a nonnucleoside antiherpesvirus compound available for the treatment of varicella-zoster virus infections. "( Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies.
den Adel, M; Groenendaal-van de Meent, D; Katashima, M; Keirns, JJ; Kowalski, D; Kusawake, T; Ohtsu, Y; Takada, A, 2017
)
2.18
"Amenamevir (ASP2151) is a nonnucleoside human herpesvirus helicase-primase inhibitor that was approved in Japan for the treatment of herpes zoster (shingles) in 2017. "( The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies.
Katashima, M; Kato, K; Keirns, JJ; Kowalski, D; Kusawake, T; Lasseter, KC; Lewand, M; Marbury, TC; Preston, RA; Takada, A, 2017
)
2.11
"Amenamevir is an inhibitor of the helicase-primase enzyme complex developed for the treatment of varicella zoster virus. "( An Open-Label, Single-Dose, Human Mass Balance Study of Amenamevir in Healthy Male Adults.
den Adel, M; Groenendaal-van de Meent, D; Katashima, M; Kato, K; Ohtsu, Y; Takada, A, 2019
)
2.2
"Amenamevir is an antiherpes agent that does not have a nucleic acid-like structure, and exerts antiviral action by inhibiting the enzymatic activity of a virus-derived helicase-primase complex, which is considered essential for viral DNA replication."( [Pharmacological profiles and clinical effects of amenamevir tablet as treatments for herpes zoster].
Kikukawa, Y; Maeda, H; Nakamura, H,
)
1.11
"Amenamevir is a novel drug that targets the viral helicase-primase complex. "( Integrative pharmacokinetic-pharmacodynamic modeling and simulation of amenamevir (ASP2151) for treatment of recurrent genital herpes.
Chono, K; Kaibara, A; Katashima, M; Katsumata, K; Sawamoto, T; Suzuki, H; Takada, A; Yano, Y, 2016
)
2.11

Effects

ExcerptReferenceRelevance
"Amenamevir has a different action mechanism from previously approved synthetic nucleoside compounds for the treatment of HZ including acyclovir, valacyclovir and famciclovir."( Pharmaceuticals and Medical Device Agency approval summary: Amenamevir for the treatment of herpes zoster.
Asakura, W; Fukuda, K; Horiuchi, T; Hoshino, Y; Minami, H; Noda, S; Sasaki, A; Shoji, N; Tanese, K; Utsuno, Y, 2020
)
1.52
"Amenamevir has been approved for the treatment of herpes zoster (HZ); however, its therapeutic efficacy against central nervous system (CNS) infection may be insufficient due to its low spinal fluid permeability. "( Aseptic Meningitis after Amenamevir Treatment for Herpes Zoster in the First Branch of the Trigeminal Nerve.
Itoh, K; Iwasaki, H; Kiriba, C; Kuwata, A; Mitsuke, Y; Otsuki, N; Sakamaki, I; Suzuki, Y; Tsutani, H; Wakahara, M; Yoshioka, T, 2022
)
2.47

Pharmacokinetics

Amenamevir increased peak concentration and area under the concentration-time curve of montelukast by about 22% (ratio 121) However, it is unlikely that renal impairment will have a significant effect on the safety of amenamevir.

ExcerptReferenceRelevance
" Here, to determine and analyze the correlation between the pharmacodynamic (PD) and pharmacokinetic (PK) parameters of ASP2151, we examined the PD profile of ASP2151 using in vitro plaque reduction assay and a murine model of HSV-1 infection."( Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection.
Chono, K; Kato, K; Katsumata, K; Kontani, T; Ohtsu, Y; Suzuki, H; Takakura, S, 2013
)
0.39
" We present a first population pharmacokinetic (PPK) modeling analysis of Amenamevir for genital herpes patients."( Statistical analysis of Amenamevir (ASP2151) between pharmacokinetics and clinical efficacies with non-linear effect model for the treatment of genital herpes.
Kaibara, A; Katashima, M; Keirns, J; Sawamoto, T; Takada, A; Zhang, W, 2014
)
0.94
"Amenamevir had less than dose proportional pharmacokinetic characteristics."( Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies.
den Adel, M; Groenendaal-van de Meent, D; Katashima, M; Keirns, JJ; Kowalski, D; Kusawake, T; Ohtsu, Y; Takada, A, 2017
)
2.18
"In the hepatic impairment study, the pharmacokinetic profile of amenamevir in participants with moderate hepatic impairment was generally similar to that of participants with normal hepatic function."( The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies.
Katashima, M; Kato, K; Keirns, JJ; Kowalski, D; Kusawake, T; Lasseter, KC; Lewand, M; Marbury, TC; Preston, RA; Takada, A, 2017
)
0.91
" However, it is unlikely that renal impairment will have a significant effect on the safety of amenamevir given that in previous pharmacokinetic and safety studies in healthy individuals amenamevir was safe and well tolerated after a single dose (5-2400 mg, fasted condition) and repeated doses for 7 days (300 or 600 mg, fed condition), and the amount of amenamevir exposure in the renal impairment study was covered by those studies."( The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies.
Katashima, M; Kato, K; Keirns, JJ; Kowalski, D; Kusawake, T; Lasseter, KC; Lewand, M; Marbury, TC; Preston, RA; Takada, A, 2017
)
0.89
"  Amenamevir increased peak concentration and area under the concentration-time curve of montelukast by about 22% (ratio 121."( Amenamevir: Studies of Potential CYP2C8- and CYP2B6-Mediated Pharmacokinetic Interactions With Montelukast and Bupropion in Healthy Volunteers.
Adeloye, T; Dennison, J; Endo, T; Johnston, A; Puri, A; Warrington, S, 2018
)
2.64

Bioavailability

ExcerptReferenceRelevance
"Four randomized phase 1 studies investigated the safety and pharmacokinetics of single and multiple doses of amenamevir, including the assessment of age group effect (nonelderly vs elderly), food effect, and the relative bioavailability of two formulations."( Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies.
den Adel, M; Groenendaal-van de Meent, D; Katashima, M; Keirns, JJ; Kowalski, D; Kusawake, T; Ohtsu, Y; Takada, A, 2017
)
0.95
" Bioavailability was 40% after single oral administration."( Absorption, Distribution, Metabolism, and Excretion of the Novel Helicase-Primase Inhibitor, Amenamevir (ASP2151), in Rodents.
Noguchi, K; Ohtsu, Y; Susaki, Y, 2018
)
0.7

Dosage Studied

ExcerptRelevanceReference
" A total of 156 HSV strains were isolated prior to the dosing of patients, and no preexisting variants with less susceptibility to ASP2151 or acyclovir (ACV) were detected."( Susceptibility of herpes simplex virus isolated from genital herpes lesions to ASP2151, a novel helicase-primase inhibitor.
Chono, K; Katsumata, K; Kontani, T; Suzuki, H; Takakura, S; Weinberg, A, 2012
)
0.38
" In the renal impairment study, the area under the amenamevir concentration versus time curve from the time of dosing up to the time of the last sample with extrapolation to infinity of the terminal phase was increased by 78."( The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies.
Katashima, M; Kato, K; Keirns, JJ; Kowalski, D; Kusawake, T; Lasseter, KC; Lewand, M; Marbury, TC; Preston, RA; Takada, A, 2017
)
0.92
"The findings of the hepatic impairment study indicate that no dosing adjustment is required in patients with moderate hepatic impairment."( The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies.
Katashima, M; Kato, K; Keirns, JJ; Kowalski, D; Kusawake, T; Lasseter, KC; Lewand, M; Marbury, TC; Preston, RA; Takada, A, 2017
)
0.67
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1557596Half life in human Plasma2019Journal of medicinal chemistry, 08-22, Volume: 62, Issue:16
Synthetic Approaches to the New Drugs Approved During 2017.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (47)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's31 (65.96)24.3611
2020's16 (34.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.46 (24.57)
Research Supply Index4.06 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index65.31 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (18.75%)5.53%
Reviews8 (16.67%)6.00%
Case Studies6 (12.50%)4.05%
Observational0 (0.00%)0.25%
Other25 (52.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]